Avrukibart
Avrukibart (ORKA-001) is a highly specific, selective humanized anti-IL-23p19 IgG1 monoclonal antibody with a Kd of <5 pM. Avrukibart blocks IL-23-mediated STAT3 signaling and reduces IL-17 secretion. Avrukibart can be used for research on moderate-to-severe plaque psoriasis.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[3]|
STAT3 |
IL-17 |
IL-23p19 <5 pM (Kd) |
In Vitro
Avrukibart (0.01 nM-1000 nM) inhibits IL-17 in cell-based assays with potency similar to the control antibody[2].
Avrukibart binds IL-23p19 via SPR with an affinity below 5 pM[3].
Avrukibart binds the IL-23p19 epitope by cryo-EM, and this epitope is nearly identical to the epitope of the benchmark antibody[3].
Avrukibart inhibits IL-23-induced STAT3 activity in HEK reporter cells, with potency comparable to or better than that of benchmark anti-IL-23p19 antibodies[3].
Avrukibart inhibits pSTAT3 in DB cells with potency comparable to or better than that of the benchmark anti-IL-23p19 antibody[3].
Avrukibart inhibits IL-23-induced IL-17 release in mouse splenocytes, with potency comparable to or better than that of the benchmark anti-IL-23p19 antibody[3].
Avrukibart inhibits IL-23-induced IL-17 release in PBMCs, with potency comparable to or better than that of the benchmark anti-IL-23p19 antibody[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Target
IL-23p19/IL-23A
Application
ELISA, FACS, Functional assay
Product Details
-
Synonyms ORKA-001
-
Species Reactivity
Human
-
Conjugated
Unconjugated
Product Properties
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)